A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT04557098
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Hematological Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Teclistamab — DRUG
    Teclistamab will be administered SC.

Study Details

The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

Key Dates

Start date
Sep 17, 2020
Status verified
Jun 2026
Primary completion
Nov 9, 2021
Completion
May 28, 2027

Study Design

Enrollment
194 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Part 3: Teclistamab
    Participants will receive teclistamab subcutaneously (SC) at recommended Phase 2 dose (RP2D) in Cohort A and Cohort C.

Primary Outcome Measure

Cohorts A and C: Overall Response Rate (ORR) [ Time Frame: Up to 2.9 years ]

Locations (10)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294-
City of HopeDuarteCalifornia91010-
University of California San FranciscoSan FranciscoCalifornia94143-
Stanford University Medical CenterStanfordCalifornia94305-5623-
Winship Cancer Institute Emory UniversityAtlantaGeorgia30322-
Barbara Ann Karmanos Cancer InstituteDetroitMichigan48201-
Icahn School of Medicine at Mount Sinai Program for the Protection of Human SubjectsNew YorkNew York10029-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10065-
Levine Cancer InstituteCharlotteNorth Carolina28204-
University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, ALCity of Hope· Duarte, CAUniversity of California San Francisco· San Francisco, CAStanford University Medical Center· Stanford, CAWinship Cancer Institute Emory University· Atlanta, GABarbara Ann Karmanos Cancer Institute· Detroit, MI

Related Studies